News
-
-
-
PRESS RELEASE
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
BioVersys announces the first patient dosed in a Phase 2b clinical trial of AlpE for pulmonary tuberculosis, collaborating with GSK under UNITE4TB project. Results expected by end of 2027 -
-
-
-
-
-
PRESS RELEASE
Accelleron delivers another year of outstanding growth and profitability
Accelleron delivers another year of outstanding growth and profitability in 2025. Revenues increased by 23.5% to USD 1.263 billion, Operational EBITA up by 22.6%, Net income rose by 35.8%. Dividend and share buyback program announced -
PRESS RELEASE
EPIC Suisse AG reports increase in rental income and profitability for FY 2025
EPIC Suisse AG reports increase in rental income by 3.0% to CHF 68.2 million for FY 2025, with improved profitability. Annual results include strong EBITDA growth, capital increase, and proposed dividend raise